Onyx Pharmaceuticals




News and Media        
Onyx Pharmaceuticals

PRESS RELEASES
--------
Press Releases

To Onyx's knowledge, all press releases, scientific papers, and abstracts and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. Onyx has no intention of updating this information, and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

Email Alerts

Sign up here to receive press releases via email.
  Submit



  • Dec. 04, 2006
Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
  • Dec. 04, 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
  • Nov. 07, 2006
Onyx Pharmaceuticals Reports Third Quarter And Nine-Month 2006 Financial Results
  • Nov. 01, 2006
Onyx Pharmaceuticals Announces Third Quarter 2006 Financial Results Teleconference And Webcast
  • Oct. 12, 2006
Onyx Pharmaceuticals to Present at BIO Investor Forum Conference
  • Sep. 29, 2006
Onyx Secures Equity Financing Commitment
  • Aug. 08, 2006
Onyx Pharmaceuticals Reports Second Quarter And Six-Month 2006 Financial Results
  • Aug. 01, 2006
Onyx Pharmaceuticals Announces Second Quarter 2006 Financial Results Teleconference And Webcast
  • Jul. 24, 2006
Nexavar Approved by European Commission for the Treatment of Advanced Kidney Cancer
  • Jul. 20, 2006
Nexavar Receives FDA Fast Track Designation for Skin Cancer
  • Jun. 13, 2006
Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
  • Jun. 12, 2006
Onyx Names Laura A. Brege Executive Vice President And Chief Business Officer
  • Jun. 06, 2006
Onyx Pharmaceuticals To Present At Two Upcoming Healthcare Conferences
  • Jun. 05, 2006
Updated Overall Survival Analysis Presented on Nexavar Phase III Trial
  • Jun. 01, 2006
Onyx Pharmaceuticals To Webcast Analyst Briefing
  • May 25, 2006
Onyx Pharmaceuticals To Present At Friedman Billings Ramsey Growth Investor Conference
  • May 10, 2006
Onyx Pharmaceuticals To Present At Bank Of America Healthcare Conference
  • May 04, 2006
Onyx Pharmaceuticals Reports First Quarter 2006 Financial Results
  • May 03, 2006
Enrollment Completed in Phase III Studies of Nexavar for Patients With Metastatic Melanoma and Liver Cancer
  • Apr. 28, 2006
Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use
  • Apr. 27, 2006
Onyx Pharmaceuticals To Present At Morgan Stanley Global Healthcare Unplugged Conference
  • Apr. 27, 2006
Onyx Pharmaceuticals Announces First Quarter 2006 Financial Results Teleconference And Webcast
  • Apr. 26, 2006
FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
  • Apr. 18, 2006
European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
  • Mar. 30, 2006
Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
  • Mar. 24, 2006
Onyx Pharmaceuticals To Present At Future Leaders In The Biotech Industry Conference
  • Mar. 02, 2006
Onyx Pharmaceuticals To Present At Two Upcoming Healthcare Conferences
  • Feb. 16, 2006
Onyx Pharmaceuticals Reports Fourth Quarter And Year-End 2005 Financial Results
  • Feb. 16, 2006
Bayer and Onyx Initiate Phase III Non-Small Cell Lung Cancer Trial Studying Nexavar (sorafenib) Tablets in Combination With Two Chemotherapeutic Agents
  • Feb. 09, 2006
Onyx Pharmaceuticals Announces Fourth Quarter And Year-End 2005 Financial Results Teleconference And Webcast
  • Feb. 08, 2006
Onyx Pharmaceuticals To Present At BIO CEO & Investor Conference
  • Jan. 31, 2006
Onyx Pharmaceuticals To Present At Merrill Lynch Global Pharmaceutical, Biotechnology And Medical Device Conference
  • Jan. 05, 2006
Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference




--------

©2008 Onyx Pharmaceuticals, Inc.